ReviewAdvanced biomedical research2025
Implications of Quercetin in Mitigating Myocardial Ischemia-Reperfusion Injury: A Review Study.
Review in Advanced biomedical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Quercetin-associated cardioprotection in preclinical myocardial ischemia-reperfusion injury: a systematic review and meta-analysis.Frontiers in pharmacology · 2026Pooled it
- Shenqi Granules Enhance Recovery from Myocardial Ischemia-Reperfusion Injury by Downregulating MMP9 and ADH1C.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Cardiac Ischaemia-Reperfusion Injury: Pathophysiology, Therapeutic Targets and Future Interventions.Biomedicines · 2025Review
- Targeting SIRT1: A Potential Strategy for Combating Severe COVID-19.BioMed research international · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myocardial ischemia-reperfusion injury (IRI) is introduced as a typical cardiovascular disorder with enhancing worldwide occurrence. It is generally persuaded via normal blood flow restoration to the ischemic myocardium after a recanalization period and instantly results in myocardial damage. Current investigations displays that flavonoids have the capability to function as cardioprotective agents versus IRI, which are faced in the myocardium. In this comprehensive review, we aim to delineate the therapeutic effects of quercetin in the context of myocardial IRI, shedding light on its potential as a cardioprotective agent. An up-to-date review of the literature on the cardioprotective impact of quercetin in myocardial IRI was conducted through Embase, all databases correlated to Science Direct, and Pubmed using the terms "myocardial ischemia", "reperfusion injury" and "quercetin". Quercetin exhibits protective effects against IRI through its anti-inflammatory, antioxidant, antiapoptotic, and calcium overload-reducing activities. The present review can emerge as a reference for planning a daily diet to prohibit or alleviate injuries following myocardial IRI and emerging flavonoids as a new window for clinical application.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.